Navigation Links
Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009

SAN DIEGO, Sept. 1 /PRNewswire/ -- Chulho Park, Ph. D., Head of Process Sciences at aTyr Pharma, a privately held biopharmaceutical company focused on discovery and development of a newly emerging class of natural biotherapeutics, will be a featured speaker at Bio Korea 2009. On September 18, 2009, Dr. Park will present his talk "Selecting the Optimal Biotherapeutic Candidate for Development" at the conference, taking place in Seoul, Korea. In his presentation, Dr. Park will discuss key steps required to create a development process for a new biotherapeutic, and how he has applied his experience to optimizing the development pathway for the lead program at aTyr Pharma. aTyr's lead program, scheduled for a pre-IND meeting at the FDA in September, is a novel protein therapeutic, ATYR0030, with thrombopoietic activity that is initially being developed to treat thrombocytopenia in patients with myelodyspastic syndromes (MDS).

After completing a Ph. D. at Korea University and postdoctoral training at Stanford University, Dr. Park has spent 9 years in the pharmaceutical industry focused on process development for biotherapeutics, including experience with 8 proteins that have reached the clinical development stage. According to Alain Vasserot, Ph. D., Executive Director of Preclinical Development at aTyr Pharma, "Dr. Park adds valuable drug development expertise to aTyr Pharma. His experience and perspective have been an essential driver in our rapid development of ATYR0030. Dr. Park's talk at Bio Korea 2009 will give attendees a prime opportunity to gain perspective from a highly skilled practitioner in the biotherapeutic development field."

Jeff Watkins, the CEO of aTyr Pharma adds, "Dr. Park is a vital component of our strong biologics development team, a strength that distinguishes aTyr Pharma from many other biotechnology companies. With the current emphasis on protein biologics, most pharmaceutical companies are looking to novel biotherapeutics to provide new treatments for human diseases. Scientific leaders in our sector understand the unique issues and challenges associated with process development for protein therapeutics, and we are pleased that the organizers of Bio Korea 2009 recognize the value of sharing Dr. Park's perspectives in biotherapeutic development."

About aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery of an entirely new class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel therapeutics to treat hematological disorders, neurodegenerative diseases, inflammation, cardiovascular diseases and metabolic disorders.

SOURCE aTyr Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
2. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
3. InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International
4. Brain Waves Show Sound Processing Abnormalities in Autistic Children
5. Stress-Related Disorders Affect Brains Processing of Memory
6. Verification Studies of IntelligentMDxs Proprietary Molecular Diagnostic Assay Process Have Been Completed
7. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
8. Smithfield Sends Update to Employees on Testing Process at Veracruz Joint Venture
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
Post Your Comments:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):